Sequencing of tumors and drugs targeted to mutations found in those cancers are beginning to change how cancer is treated, the Wall Street Journal reports.

The newspaper focuses on Kellie Carey, a lung cancer patient who was given a few months to live back in 2010. But through persistence, Carey persuaded her physicians to genotype her tumor, and they uncovered that she had an ALK gene mutation that could be targeted by Pfizer's Xalkori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Between the Coasts

In a Name

Peace of Mind

The Pair of Them

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.